ES2010230A6 - Metodo para fabricar particulas de proteinas de fusion con parte de su secuencia homologa a proteinas de hiv y metodo para expresar dichas proteinas. - Google Patents

Metodo para fabricar particulas de proteinas de fusion con parte de su secuencia homologa a proteinas de hiv y metodo para expresar dichas proteinas.

Info

Publication number
ES2010230A6
ES2010230A6 ES8703104A ES8703104A ES2010230A6 ES 2010230 A6 ES2010230 A6 ES 2010230A6 ES 8703104 A ES8703104 A ES 8703104A ES 8703104 A ES8703104 A ES 8703104A ES 2010230 A6 ES2010230 A6 ES 2010230A6
Authority
ES
Spain
Prior art keywords
amino acid
acid sequence
hiv antigens
hybrid hiv
particulate hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8703104A
Other languages
English (en)
Inventor
Alan J Kingsman
Susan M Kingsman
Sally Elizabeth Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
Oxford Gene Systems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868626148A external-priority patent/GB8626148D0/en
Priority claimed from GB878708532A external-priority patent/GB8708532D0/en
Application filed by Oxford Gene Systems Ltd filed Critical Oxford Gene Systems Ltd
Publication of ES2010230A6 publication Critical patent/ES2010230A6/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

METODO PARA FABRICAR PARTICULAS DE PROTEINAS DE FUSION CON PARTES DE SUS SECUENCIAS HOMOLOGAS A PROTEINAS DE HIV Y METODO PARA EXPRESAR DICHAS PROEINAS Y OBTENER VACUNAS, EN DONDE SE TRANSFORMAN CELULAS DE BACTERIAS, LEVADURAS O MAMIFEROS CON UN VECTOR QUE CONTIENE UNA SECUENCIA DE ADN QUE CODIFICA LAS PROTEINAS, SE HACEN CRECEN LAS CELULAS TRANSFORMADAS EN UN MEDIO DE CULTIVO Y SE AISLAN LAS PARTICULAS FORMADAS, COMPRENDIENDO CADA PROTEINA UNA SECUENCIA DE AMINOACIDOS SUSTANCIALMENTE HOMOLOGA A UNA PROTEINA FORMADORA DE PARTICULAS CODIFICADA POR UN RETROTRANSPOSON O UN RETROVIRUS DE ARN, Y OTRA SECUENCIA DE AMINOACIDOS SUSTANCIALMENTE HOMOLOGA A UNA PROTEINA DE HIV. LAS PROTEINAS SE EXPRESAN TRANSFORMANDO LAS CELULAS CON UN VECTOR QUE CONTIENE SECUENCIAS DE NUCLEOTIDOS APROPIADAS, HACIENDO CRECER LAS CELULAS TRANSFORMADAS Y AISLANDO LA PROTEINA. EL INVENTO ES UTIL PARA PREPARAR VACUNAS CONTRA EL VIRUS DE INMUNODEFICIENCIA HUMANA.
ES8703104A 1986-11-01 1987-10-30 Metodo para fabricar particulas de proteinas de fusion con parte de su secuencia homologa a proteinas de hiv y metodo para expresar dichas proteinas. Expired ES2010230A6 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB868626148A GB8626148D0 (en) 1986-11-01 1986-11-01 Antigen presentation & purification system
GB878708532A GB8708532D0 (en) 1987-04-09 1987-04-09 Particulate hybrid hiv antigens
US3688887A 1987-04-10 1987-04-10

Publications (1)

Publication Number Publication Date
ES2010230A6 true ES2010230A6 (es) 1989-11-01

Family

ID=27263195

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8703104A Expired ES2010230A6 (es) 1986-11-01 1987-10-30 Metodo para fabricar particulas de proteinas de fusion con parte de su secuencia homologa a proteinas de hiv y metodo para expresar dichas proteinas.

Country Status (8)

Country Link
EP (1) EP0329671B1 (es)
JP (1) JPH02501107A (es)
AU (1) AU606627B2 (es)
DE (1) DE3788806T2 (es)
ES (1) ES2010230A6 (es)
HU (1) HUT50875A (es)
NO (1) NO177794C (es)
WO (1) WO1988003562A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3006789A (en) * 1988-02-24 1989-08-24 Smithkline Beckman Corporation Expression of hiv binding proteins
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
EP0361749B1 (en) * 1988-09-27 1995-02-08 Dana Farber Cancer Institute A vector comprising a replication competent HIV-I provirus and a heterologous gene
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
WO1990005787A1 (en) * 1988-11-23 1990-05-31 The Regents Of The University Of California Position-specific insertion vectors and method of using same
JP3034025B2 (ja) * 1989-06-01 2000-04-17 アプライド・バイオテクノロジー・インコーポレーテツド 自己アセンブルド欠損非自己増殖性ウイルス粒子
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5989886A (en) * 1991-01-02 1999-11-23 The Johns Hopkins University Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme
GB9107631D0 (en) * 1991-04-10 1991-05-29 British Bio Technology Proteinaceous particles
CA2118026A1 (en) * 1992-04-14 1993-10-28 Guy T. Layton Induction of ctl responses
WO1994016084A1 (en) * 1993-01-16 1994-07-21 British Bio-Technology Limited Hybrid particle-forming protein comprising a particle-inducing segment and a plurality of antigens
FR2703996B1 (fr) 1993-04-16 1995-07-21 Transgene Sa Ensemble de transposition destine au transfert d'un gene d'interet dans le genome d'une cellule eucaryote.
CA2164298A1 (en) 1993-06-04 1994-12-22 Richard A. Young Stress proteins and uses therefor
DE4335025A1 (de) * 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
WO1998029551A1 (en) * 1997-01-02 1998-07-09 Universidade Federal De Minas Gerais THE PROCESS FOR EXPRESSION AND PRODUCTION OF RECOMBINANT PROTEIN HYBRID PROTEIN (p24/p17) DERIVED FROM HUMAN IMMUNODEFICIENCY VIRUSES (HIV-1)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR76274B (es) * 1981-08-04 1984-08-04 Univ California
DE3788807T2 (de) * 1986-11-01 1994-06-30 British Bio Technology Fusionsproteine und -partikel.

Also Published As

Publication number Publication date
NO177794C (no) 1995-11-22
DE3788806T2 (de) 1994-07-07
HUT50875A (en) 1990-03-28
EP0329671B1 (en) 1994-01-12
NO177794B (no) 1995-08-14
JPH02501107A (ja) 1990-04-19
EP0329671A1 (en) 1989-08-30
NO882918L (no) 1988-08-29
AU606627B2 (en) 1991-02-14
AU8153487A (en) 1988-06-01
NO882918D0 (no) 1988-06-30
DE3788806D1 (de) 1994-02-24
WO1988003562A1 (en) 1988-05-19

Similar Documents

Publication Publication Date Title
ES2010230A6 (es) Metodo para fabricar particulas de proteinas de fusion con parte de su secuencia homologa a proteinas de hiv y metodo para expresar dichas proteinas.
ES2010231A6 (es) Metodo para fabricar particulas de proteinas de fusion y metodo para expresar estas proteinas.
ATE93894T1 (de) Expressionssysteme fuer hefe mit pyk-promotoren enthaltenden vektoren und synthese von fremdproteinen.
AU591054B2 (en) Pre-S gene coded peptide hepatitis B immunogens, vaccines and diagnostics
IE822517L (en) Human immune interferon
EP1245678A3 (en) Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
ATE86636T1 (de) F antigene vom menschlichen immunodefizienz-virus und deren verwendungen.
Parish Simple model for self-non-self-discrimination in invertebrates
ATE154610T1 (de) Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung
NZ333431A (en) Multiple epitope fusion protein selected from HIV or HCV, method of immunoassay and assay device
AU5711294A (en) Novel proteinaceous particles
WO1993018055B1 (en) Peptides stimulating cytotoxic lymphocytes respone to hiv-1 gp160
EP0298633A3 (en) Synthetic polypeptides
CA2084386A1 (en) Hiv antigen
AU2567888A (en) Hiv peptides and methods for detection of hiv
EP0152030A3 (en) Adult t cell leukemia virus antigen polypeptide
WO1993018163A3 (en) Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
EP0327180A3 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
EP0293827A3 (en) Assay for leishmaniasis
Ducos et al. Hepatitis B virus (HBV)-specific in vitro antibody production by peripheral blood mononuclear cells (PBMC) after vaccination by recombinant hepatitis B surface antigen (rHBsAg)
DK362088A (da) Fusionsproteiner og fusionsproteinpartikler
GB2336844A (en) Anti-hiv peptides and proteins
AU4712993A (en) New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods
Edouard et al. Recognition by human sera of a variable region of the surface glycoprotein of HTLV-I
EP0293201A3 (en) Method of vaccination for hepatitis b virus

Legal Events

Date Code Title Description
SA6 Expiration date (snapshot 920101)

Free format text: 2007-10-30

PC1A Transfer granted

Owner name: BRITISH BIO-TECHNOLOGY LIMITED